Original articlesUrogenital tumorsRelationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302
Urogenital tumors
Under an Elsevier user license
open archive
Key words
metastatic castration-resistant prostate cancer
overall survival
pain
patient-reported outcomes
quality of life
radiographic progression-free survival
Cited by (0)
Note: This study was previously presented in part at the American Society of Clinical Oncology Annual Genitourinary Cancers Symposium, 7–9 January 2016, San Francisco, CA, and the Japanese Urological Association Annual Meeting, 23–25 April 2016, Sendai, Japan.
- †
Affiliation at the time of analysis.
- ‡
Currently an employee of Novartis.
- §
Currently an employee of Sutro Biopharma.
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.